ABSTRACT
Since the introduction of pulmonary artery catheterization for hemodynamic monitoring, several complications associated with its use have been described. Pulmonary artery rupture is an infrequent complication of flow-directed pulmonary artery catheters. We report a case of pulmonary artery rupture complicating rescue PTCA in the presence of systemic platelet inhibition with abciximab (Reopro), anticoagulation, and thrombolytic therapy. With the increasing use of these medications in patients undergoing acute coronary interventions, particularly those patients requiring hemodynamic monitoring, this uncommon but potentially fatal complication may be seen more frequently.
Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Antibodies, Monoclonal/therapeutic use , Anticoagulants/therapeutic use , Fibrinolytic Agents/therapeutic use , Immunoglobulin Fab Fragments/therapeutic use , Pulmonary Artery/injuries , Tissue Plasminogen Activator/therapeutic use , Abciximab , Aged , Aged, 80 and over , Angiography , Cardiac Catheterization , Extravasation of Diagnostic and Therapeutic Materials/etiology , Fatal Outcome , Female , Humans , RuptureABSTRACT
Cardiovascular disease is the major cause of morbidity and mortality in patients with diabetes. Diabetic individuals have a 200% to 400% greater risk for vascular disease than nondiabetics, with a disproportionately greater burden of disease complications in non-white minorities. Although the atherosclerotic plaques in the two groups are similar, diabetics have more severe and more diffuse disease than nondiabetics. Recent advances in the treatment of coronary disease have improved survival for diabetics and nondiabetics, but diabetics still have double the case fatality rate as nondiabetics, and diabetic women have particularly poor outcomes. Diabetic individuals also have an increased frequency of silent ischemia, systolic and diastolic left ventricular dysfunction, and cardiac autonomic neuropathy. The high frequency of modifiable risk factors provides great opportunities for prevention, the cornerstones of therapy being glycemic control, aggressive risk factor modification, and ongoing patient surveillance and monitoring to facilitate early disease detection and prompt intervention. In patients with coronary disease who require revascularization, both mechanical coronary interventions and bypass surgery are effective therapies. Patients with multivessel coronary disease have better results following bypass surgery with arterial grafts than following coronary interventions. However, diabetic patients are at increased risk for poor long-term outcome following either revascularization modality, with high rates of restenosis following mechanical interventions and the development of atherosclerosis in conduits following bypass surgery.
